Vor Biopharma (VOR)
(Real Time Quote from BATS)
$0.83 USD
+0.01 (1.31%)
Updated Aug 13, 2024 12:54 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
VOR 0.83 +0.01(1.31%)
Will VOR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VOR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VOR
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
VOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
Can Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect?
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 295%
Other News for VOR
Buy Rating Backed by Clinical and Financial Strengths at Vor Biopharma
Buy Rating Affirmed for Vor Biopharma Amid Anticipated Clinical Trials and Strong Financial Footing
VOR Stock Earnings: Vor Biopharma Beats EPS for Q2 2024
Wedbush Keeps Their Buy Rating on Vor Biopharma (VOR)
Optimistic Outlook on Vor Biopharma’s Pipeline and Financial Stability Drives Buy Rating